Middle-East and Africa Dermatology Drug Markets Likely to grow at a CAGR of 7% during 2021-2026

According to the MarkNtel Advisors' research report, "Middle-East and Africa Dermatology Drug Market Analysis, 2021," the Drug Market is likely to grow at a CAGR of around 7% during 2021-26. The growth of the Middle-East and Africa Dermatology Drug Market attributes to the surge in skin diseases and rising awareness regarding treatment and diagnostic of skin-related problems such as acne, dermal ulcer, alopecia, etc.

Nowadays, acnes are the most commonly occurring skin problem among the young generation concerning physical appearance. Therefore, there is a high demand for dermatological drugs among youth. Moreover, burgeoning R&D activities to develop a diverse product portfolio in dermatology drugs and the snowballing number of mergers & acquisitions can provide incredible growth opportunities to boost the market in the forecast timeline.

Get the sample pages of the report: https://www.marknteladvisors.com/query/request-sample/middle-east-africa-dermatology-drugs-market.html

Key questions answered in the study
1. What are the current and future trends in Middle-East and Africa Dermatology Drug Market?
2. How has the market been evolving in terms of end-user demand and application areas?
3. How has the competition been shaping across the countries, followed by their comparative factorial indexing?
4. What are the key growth drivers and challenges for Middle-East and Africa Dermatology Drug Market?
5. What are the customer orientation, purchase behavior, and expectations from the Middle-East and Africa Dermatology Drug Market service provider across various Countries?

Acne Segment Show a Substantial Growth
Within Applications, the market segments into Psoriasis, Atopic dermatitis, Acne, Rosacea, Skin cancer, and Scars. The Acne segment is likely to grow considerably during the forecast period owing to the high demand for acne-related dermatology drugs. It is because the maximum population aged between 12-24 suffers minor acne problems.

Further, the prevalence of acne is also increasing among the adult population due to various reasons such as climatic change, increase in stress level, and bacteria build-up, which further contributes lucrative opportunities for the overall growth of the dermatology drug market.

For detailed analysis: https://www.marknteladvisors.com/research-library/middle-east-africa-dermatology-drugs-market.html

"Middle-East and Africa Dermatology Drug Market Analysis, 2021" provides comprehensive qualitative and quantitative insights on the market potential, key factors impacting the market growth, hotspots, and opportunities available for dermatology drug providers across the country. Moreover, the report also encompasses the key strategic imperatives for the competitors' success and strategic factorial indexing measuring competitors' capabilities on 16 parameters, which will help companies formulate 'Go to Market' strategies and identify the blue ocean for their offerings.

Prescription based drugs Expected to register robust growth
Based on Prescription Mode, the market segments into prescription-based and OTC drugs. The Prescription-Based drugs certainly can grow considerably in the Middle-East and Africa Dermatology Drug Market during the forecasted period due to mounting awareness regarding skin diseases and the rising number of people consulting dermatologists.

Moreover, the surging dermatological clinics have enabled easy availability of prescription-based drugs, thereby boosting the market growth, says MarkNtel Advisors in their research report, "Middle-East and Africa Dermatology Drug Market Analysis, 2021."

According to MarkNtel Advisors, the major leading players in the GCC Facility Management market are Bausch Health Companies Inc., Mylan N.V., Novartis AG, Bristol-Myers Squibb Company, Johnson & Johnson, Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Eli Lilly and Company, Amgen Inc., Galderma S.A., GlaxoSmithKline plc.

Market Segmentation:
1. By Drug Type (Branded, Generics)
2. By Drug Class (Corticosteroids, Retinoid, Monoclonal Antibodies, Antibiotics Agents, Antiviral Agents, Antifungal Drugs, Antihistamines Agents, Immunosuppressive Drugs)
3. By Application (Psoriasis, Atopic dermatitis, Acne, Rosacea, Skin cancer, Scar, Others)
4. By End Users (Hospitals, Cosmetic-Centers, Dermatology Clinics, Homecare, Others)
5. By Prescription Mode (Prescription Based Drugs, OTC Drugs)
6. By Route of Administration (Topical, Oral, Parenteral)
7. By Distribution Channel (Direct, Retail/wholesale, Online)
8. By Geographic Region (UAE, Saudi Arabia, Qatar, Turkey, South Africa)
9. By Competitors (Bausch Health Companies Inc., Novartis AG, Pfizer Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co. Inc., Amgen Inc., AbbVie Inc., Eli Lilly and Company, Galderma S.A., GlaxoSmithKline plc, Mylan N.V.)

MarkNtel Advisors
Office No.106, H-160, Noida - 63, UP- 201301
India
Email: sales@marknteladvisors.com
Tel: +91 120 4185243
Website: https://www.marknteladvisors.com

MarkNtel Advisors is a leading research, consulting and data analytics firm that provides a wide range of strategic reports on diverse industry verticals to a substantial and varied client base that includes multinational corporations, financial institutions, governments, and individuals.

We specialize in niche industries and emerging geographies to support our clients in the formulation of strategies viz. Go to Market (GTM), product development, feasibility analysis, project scoping, market segmentation, competitive benchmarking, market sizing & forecasting, trend analysis, etc. in around 15 industry verticals to enable our clients in identifying attractive investment opportunities and maximizing ROI through an early mover advantage.

This release was published on openPR.